Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.

By P. Mease, D. Gladman, C. Ritchlin, E. Ruderman, S. Steinfeld, E. Choy, J. Sharp, P. Ory, R. Perdok, M. Weinberg. Arthritis & Rheumatism, 2005

917 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment (2009, background): “11 Therapeutic trials of highly effective biological therapies such as tumour necrosis factor (TNF) blockers in PsA have shown a reduction in disease activity and a corresponding reduction in radiological progression.(12) 13 However, the lack of criteria or cut-off points for remission or low diseas”